Fundraising FoxBioVentures — Full Portfolio
4 tracked investments · listed companies and verified rows first
Profusa develops injectable hydrogel biosensors and AI-driven health platforms that enable real-time measurement of body chemistry from within tissue.
AI & Machine LearningDigital HealthHealthtechMedical DevicesSan Francisco, US
Bill Fawcett(Co-founder)Natalie Wisniewski(Executive Officer, Director)inBill McMillan(Co-Founder, CSO & Head of Research)Ben Healy(CEO)Ben Hwang(Chairman & CEO)in
Board seatQianye Karen Liu· per SEC Form D · $17M raise · filed Jul 2015
Co-investors3E Bioventures CapitalAsset Management CompanyAtinum Investment Co. Ltd.Sand Hill Angels
Avirmax is a preclinical-stage biopharmaceutical company developing AAV-based genetic medicines to treat chronic and degenerative ocular diseases.
BiotechDeep TechMedical DevicesHayward, US
Haifeng Chen(Director and Treasurer of the Issuer)inShengjiang Liu(Executive Officer, Director)
BoardNancy Chang(Director of the Issuer)
Board seatQianye Karen LiuYu Fang· per SEC Form D · $10M raise · filed Nov 2019
Co-investors3E Bioventures Capital
Purinomia is a clinical-stage biotechnology company developing therapeutics for cancer and inflammatory diseases.
BiotechHealthtechWeston, US
CEO & Scientific Founder(CEO & Scientific Founder)Yan Wu(CEO & Scientific Founder)Haitao Zhao(Scientific Founder)Simon Robson(Scientific Founder)in
Board seatQianye Karen Liu· per SEC Form D · $3.8M raise · filed May 2020
HydroCision develops minimally invasive surgical instruments using proprietary FluidJet technology to selectively remove soft tissue in a precise manner.
BiotechHardwareHealthtechMedical DevicesNorth Billerica, US
PAUL KOWALSKI(Executive Officer)inRICHARD A. LYTLE, III(Executive Officer, Director)THOMAS D. ABERT(Executive Officer)inPATRICIA VANBLARCOM(Executive Officer)Rick Lytle(President & Chief Executive Officer)in
BoardLONG ZHAN(Director)
Co-investorsNewbury VenturesOxford Bioscience Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.